Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DaTtrace-123 is an iodine-123 labeled dopamine transporter imaging radiopharmaceutical developed and marketed by Samyoung Unitech for neurological diagnostic imaging. It is used in dopamine transporter single-photon emission computed tomography to visualize presynaptic dopaminergic nerve terminal integrity in the striatum, supporting evaluation of Parkinsonian syndromes and differentiation of degenerative parkinsonism from disorders without dopaminergic deficit. The agent functions as a small-molecule radioligand that binds the dopamine transporter in the brain and is listed as an approved marketed radiopharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DaTtrace-123.